Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.

[1]  T. Das,et al.  Theranostic Applications of Lutetium-177 in Radionuclide Therapy. , 2016, Current radiopharmaceuticals.

[2]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[3]  F. Knapp,et al.  Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment. , 2015, Current radiopharmaceuticals.

[4]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[5]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[6]  S. Basu,et al.  Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases , 2015, The Journal of Nuclear Medicine.

[7]  E. Demirci,et al.  Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[9]  S. Chakraborty,et al.  Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of 177Lu-Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience , 2015, World journal of nuclear medicine.

[10]  R. Wahl,et al.  Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts , 2015, The Journal of Nuclear Medicine.

[11]  M. R. A. Pillai,et al.  Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. , 2015, Chemical reviews.

[12]  U. Haberkorn,et al.  [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  A. Kopp-Schneider,et al.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  M. R. Raghavendra Rao,et al.  177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[17]  M. Pomper,et al.  Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). , 2013, Journal of medicinal chemistry.

[18]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  William C. Eckelman,et al.  First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[20]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[21]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[22]  S. Tagawa,et al.  Prostate-Specific Membrane Antigen-Based Therapeutics , 2011, Advances in urology.

[23]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[24]  A. Kozikowski,et al.  A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. , 2009, Journal of medicinal chemistry.

[25]  S. Novaković,et al.  Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma , 2007 .

[26]  M. Pillai,et al.  Production logistics of 177Lu for radionuclide therapy. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[27]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[28]  G. Arora,et al.  177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  M. Pillai,et al.  Options to meet the future global demand of radionuclides for radionuclide therapy. , 2013, Nuclear medicine and biology.

[30]  A. Jemal,et al.  Global Cancer Statistics , 2011 .